Videos

Ajay K. Gopal, MD, discusses the rationale for treating a 69-year-old woman with high-risk follicular lymphoma with a PI3-kinase inhibitor in the third-line setting.

A group of physicians in gynecologic oncology spoke to the challenges they have seen in their clinics in the face of the COVID-19 pandemic.

Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.

Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.

Bradley J. Monk, MD, FACS, FACOG, discusses the remaining challenges in conducting clinical trials for patients with cervical cancer.

Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.

Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.

Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.

Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.

Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.

Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.